Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 10/20 | 0.52 |
| ▸ | ADA | P00813 | 1/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 10/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 6/20 | 0.42 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.42 |
| ▸ | AHCY | P23526 | 1/20 | 0.40 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.38 |
| ▸ | DNMT3B | Q9UBC3 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18852326 | 1.00 | ADORA2A (0.52) | ADORA2AADAADORA3ADORA1ADORA2B | |
| SCHEMBL15868513 | 1.00 | ADORA2A (0.52) | ADORA2AADAADORA3ADORA1ADORA2B | |
| SCHEMBL14929096 | 1.00 | ADORA2A (0.52) | ADORA2AADAADORA3ADORA1ADORA2B | |
| SCHEMBL14946104 | 1.00 | ADORA2A (0.52) | ADORA2AADAADORA3ADORA1ADORA2B | |
| SCHEMBL14928477 | 1.00 | ADORA2A (0.52) | ADORA2AADAADORA3ADORA1ADORA2B | |
| SCHEMBL18852312 | 1.00 | ADORA2A (0.52) | ADORA2AADAADORA3ADORA1ADORA2B | |
| SCHEMBL14946110 | 1.00 | ADORA2A (0.52) | ADORA2AADAADORA3ADORA1ADORA2B | |
| SCHEMBL15293104 | 0.91 | ADORA2A (0.42) | ADORA2AADAADORA3ADORA1ADORA2B | |
| SCHEMBL17789317 | 0.91 | ADORA2A (0.42) | ADORA2AADAADORA3ADORA1ADORA2B | |
| SCHEMBL15780890 | 0.91 | ADORA2A (0.42) | ADORA2AADAADORA3ADORA1ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9827332-B2 | Modified polynucleotides for the production of proteins | MODERNATX, INC. (US) | 2017-11-28 | — | — | US | disclosed |
| US-20140193482-A1 | MODIFIED POLYNUCLEOTIDES ENCODING V-MYC AVIAN MYELOCYTOMATOSIS VIRAL ONCOGENE HOMOLOG | MODERNA THERAPEUTICS, INC. (US) | 2014-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140193482-A1 | MODIFIED POLYNUCLEOTIDES ENCODING V-MYC AVIAN MYELOCYTOMATOSIS VIRAL ONCOGENE HOMOLOG | MYC, MYCBP, POLN | ADORA2A 2492/4885ADA 539/4885ADORA3 3729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.